Alzinova AB Total Assets
Alzinova AB total assets. Based on the latest financial reports, Alzinova AB (ALZ) holds total assets worth Skr158.62 Million SEK (≈ $17.07 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ALZ company net worth for the company's overall valuation and market capitalisation.
Total Assets of Alzinova AB (2012–2025)
Total assets of Alzinova AB from 2012 to 2025. This chart illustrates how Alzinova AB's total assets have evolved over time, based on quarterly financial data. See latest Alzinova AB stock price today for real-time trading data and today's change.
Alzinova AB - Asset Composition Analysis
Alzinova AB Total Assets Breakdown (December 2025)
Alzinova AB total assets breakdown as of December 2025. Alzinova AB's total assets of Skr158.62 Million consist of 1.5% current assets and 98.5% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0.2% |
| Accounts Receivable | Skr1.89 Million | 1.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr141.22 Million | 98.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Alzinova AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Alzinova AB (ALZ) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alzinova AB's current assets represent 1.5% of total assets in 2025, a decrease from 22.6% in 2012.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2025, down from 18.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 98.0% of total assets, an increase from 14.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 98.5% of total assets.
Alzinova AB Competitors by Total Assets
Key competitors of Alzinova AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Alzinova AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 0.80 | 7.72 |
| Quick Ratio | 1.37 | 0.80 | 7.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr3.38 Million | Skr-1.77 Million | Skr36.62 Million |
Alzinova AB - Advanced Valuation Insights
This section examines the relationship between Alzinova AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.39 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 7.7% |
| Total Assets | Skr143.43 Million |
| Market Capitalization | $7.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Alzinova AB's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Alzinova AB's assets grew by 7.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Alzinova AB (2012–2025)
The table below shows the annual total assets of Alzinova AB from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr143.43 Million ≈ $15.44 Million |
+7.66% |
| 2024-12-31 | Skr133.23 Million ≈ $14.34 Million |
+8.15% |
| 2023-12-31 | Skr123.19 Million ≈ $13.26 Million |
+10.36% |
| 2022-12-31 | Skr111.62 Million ≈ $12.01 Million |
+21.74% |
| 2021-12-31 | Skr91.69 Million ≈ $9.87 Million |
-9.05% |
| 2020-12-31 | Skr100.82 Million ≈ $10.85 Million |
+58.69% |
| 2019-12-31 | Skr63.53 Million ≈ $6.84 Million |
-3.87% |
| 2018-12-31 | Skr66.09 Million ≈ $7.11 Million |
+108.34% |
| 2017-12-31 | Skr31.72 Million ≈ $3.41 Million |
-4.78% |
| 2016-12-31 | Skr33.31 Million ≈ $3.58 Million |
+50.06% |
| 2015-12-31 | Skr22.20 Million ≈ $2.39 Million |
+936.44% |
| 2014-12-31 | Skr2.14 Million ≈ $230.51K |
+47.54% |
| 2013-12-31 | Skr1.45 Million ≈ $156.23K |
+29.94% |
| 2012-12-31 | Skr1.12 Million ≈ $120.23K |
-- |
About Alzinova AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide … Read more